Aperio Group’s Editas Medicine EDIT Stock Holding History

Aperio Group’s Portfolio EDIT Stock Details EDIT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2020 Q4	$1.18M	Buy	16,774 +678	+4%	+$27.9K	﹤0.01%	1504
2020 Q3	$452K	Buy	16,096 +2,343	+17%	+$76.3K	﹤0.01%	1864
2020 Q2	$407K	Sell	13,753 -244	-2%	-$6.38K	﹤0.01%	1873
2020 Q1	$278K	Buy	13,997 +3,764	+37%	+$94.9K	﹤0.01%	1949
2019 Q4	$303K	Buy	+10,233	New	+$256K	﹤0.01%	2055
2019 Q3	–	Sell	-3,394	Closed	-$84K	–	2442
2019 Q2	$84K	Buy	+3,394	New	+$81K	﹤0.01%	2431

Other funds holding EDIT

AIM

ARK Investment Management St. Petersburg, Florida $12.9B AUM 64.92% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

NAMA

Nikko Asset Management Americas New York $7.07B AUM 50.91% 1-Year Est. Return

Sumitomo Mitsui Trust Group Minato-Ku, Tokyo, Japan $175B AUM 40.63% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Federated Hermes Pittsburgh, Pennsylvania $61.5B AUM 30.7% 1-Year Est. Return

D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return

Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return

Chevy Chase Trust Bethesda, Maryland $34.7B AUM 29.45% 1-Year Est. Return

Aperio Group's EDIT Position: Q4 2020 in Review

Aperio Group increased its Editas Medicine (EDIT) stake by 4.2% in Q4 2020, buying an estimated $27.9K and bringing the position to 16,774 shares worth $1.18M. The position accounts for ﹤0.01% of the portfolio, ranked #1504.

Aperio Group first reported a position in EDIT in Q2 2019 and has held it in 6 quarters since. 312 funds tracked by Wall St. Rank hold EDIT as of Q4 2020.

Aperio Group held 16,774 shares of Editas Medicine worth $1.18M as of Q4 2020.
Aperio Group bought 678 Editas Medicine shares in Q4 2020, an estimated $27.9K.
Editas Medicine made up ﹤0.01% of Aperio Group's portfolio in Q4 2020, its #1504 holding.
Aperio Group first reported a position in Editas Medicine in Q2 2019 and has held it in 6 quarters since.
312 funds tracked by Wall St. Rank held Editas Medicine as of Q4 2020.

Based on Aperio Group's 13F filing for Q4 2020, filed 5 Feb 2021.